Atypical Chronic Myeloid Leukemia

This is a type of leukemia, which is cancer of the blood cells. It's called 'atypical' because it looks a bit different from the most common type, Chronic Myeloid Leukemia (CML). It's called 'myeloid' because it affects the myeloid cells, which are a type of blood cell. The key thing is that it doesn't have the specific genetic change (called the Philadelphia chromosome) that is usually found in CML. Doctors use this term to describe a specific group of leukemia cases that need careful monitoring.

Condition

What people with Atypical Chronic Myeloid Leukemia report

Every report comes from a Lived member, sent anonymously.

Have you tried Hydroxyurea for Atypical Chronic Myeloid Leukemia?

NameHow it went

About Atypical Chronic Myeloid Leukemia

What It Is

Atypical chronic myeloid leukemia (aCML) is a rare cancer of the blood-forming stem cells in the bone marrow. The marrow makes far too many granulocytes, a family of infection-fighting white blood cells, and many of them are released into the blood before they have matured. Over time these cells crowd out the cells that make red blood cells and platelets, which can lead to anemia, bruising or bleeding, and an enlarged spleen. Despite the similar name, aCML is a different disease from chronic myeloid leukemia (CML). Under the microscope the two can look alike, but CML is driven by a specific chromosome change called the Philadelphia chromosome, which creates the BCR-ABL1 gene. aCML does not have this change, so the targeted pills that work so well in CML are not a standard treatment for it. Doctors group aCML with conditions that have features of two kinds of marrow disorder at once: overproduction of cells, as in myeloproliferative neoplasms, and abnormally formed cells that work poorly, as in myelodysplastic syndromes. In 2022 the World Health Organization renamed it myelodysplastic/myeloproliferative neoplasm with neutrophilia (neutrophilia means a high neutrophil count), while another widely used classification kept the name aCML. Both names describe the same disease.

Causes & Risk Factors

The cause of aCML is not known. It develops when blood stem cells acquire changes in their genes during a person's lifetime. Most people with aCML have several such changes, often in genes that control how blood cells grow and how their DNA is switched on and off. These changes are found in the leukemia cells, not passed down in families, and no specific habit or exposure has been shown to cause aCML. The disease mainly affects older adults. In large studies the typical age at diagnosis is in the early 70s, and it is somewhat more common in men. It is very rare, with roughly 3 new cases per 10 million people each year in the United States.

How It's Diagnosed

aCML is often first suspected when a routine blood test shows a high white blood cell count, sometimes along with low red cells or abnormal platelet counts. A complete blood count measures each type of blood cell, and a blood smear lets a specialist look at the cells directly. In aCML, the white count is at least 13,000 cells per microliter (often reported as 13 x 10^9/L), and at least 10% of the white cells are immature granulocytes that would normally stay in the marrow. The cells also look abnormally formed. A bone marrow biopsy, in which a needle removes a small sample from the hipbone, is needed to confirm the diagnosis. The sample is examined under a microscope and tested for chromosome and gene changes. These tests do two jobs. They rule out CML by showing that the BCR-ABL1 change is absent, and they help separate aCML from close look-alikes such as chronic neutrophilic leukemia and chronic myelomonocytic leukemia. Gene testing often finds the mutations typical of aCML, and the percentage of very immature cells (blasts) must be below 20%, since a higher level would mean acute leukemia. Because aCML is rare and the criteria are detailed, it is reasonable to have the marrow and genetic results reviewed at a center that sees many blood cancers.

Treatment Options

There is no standard treatment for aCML, and the evidence comes mostly from small case series rather than large trials. For that reason, specialists encourage joining a clinical trial when one is available. The only treatment that can potentially cure aCML is an allogeneic stem cell transplant, in which the person's marrow is replaced with blood-forming cells from a matched donor. Expert transplant groups recommend considering it early after diagnosis for anyone well enough to have it. It is a demanding treatment: in published series, a meaningful share of people relapse, and some die of transplant complications such as infection or graft-versus-host disease, in which donor immune cells attack the body. Lower-intensity preparation regimens appear to work about as well in some studies, which may open transplant to more older adults. For people who are not transplant candidates, or while preparing for transplant, treatment aims to control blood counts, shrink an enlarged spleen and ease symptoms. Hydroxyurea, an oral chemotherapy pill, is the most commonly used and can bring counts down, although the effect often fades. Interferon, an injected immune treatment, is another option. Azacitidine and decitabine, drugs used for myelodysplastic syndromes, are sometimes given, and ruxolitinib (Jakafi), a targeted pill approved for other marrow disorders, can help some people, particularly those whose leukemia carries a change in the gene for the neutrophil growth-signal receptor (called CSF3R). These drugs are used off label for aCML, and none has been shown to change the long-term course of the disease. Supportive care is a large part of treatment. Many people need regular red blood cell transfusions for anemia, and treating infections and bleeding promptly matters. Removing the spleen is generally not recommended. Gene testing can also point to targeted drugs being studied for particular mutations.

What to Expect

aCML is a serious disease, and its course is usually faster than the word chronic suggests. In published studies, half of people lived about one to two years after diagnosis, although some live considerably longer and these averages come from small groups. In roughly 30 to 40% of people, aCML turns into acute myeloid leukemia (AML), a fast-growing leukemia, often within about 12 to 18 months of diagnosis. Older age, anemia and a very high white count are linked with a less favorable outlook, but there is no reliable scoring system that predicts how an individual will do. Day to day, fatigue from anemia, an uncomfortable enlarged spleen, night sweats and weight loss are common. Regular blood counts guide treatment, and many people spend substantial time at clinic visits and transfusion appointments. If transplant is an option, the process of finding a donor and preparing typically begins soon after diagnosis, so early conversations with a transplant center are part of planning.

When to Seek Help

See a doctor if you have ongoing tiredness or weakness, shortness of breath, pale skin, easy bruising or bleeding, tiny red spots under the skin, or pain or fullness below the ribs on the left side. A blood count is a simple first step. If you are being treated for aCML, contact your care team right away for a fever of 100.5 F (38 C) or higher, chills or other signs of infection, since low numbers of working white cells make infections dangerous. Also call promptly about bleeding that is hard to stop, new bruising, worsening breathlessness or rapidly increasing fatigue, which can mean counts are falling or the disease is changing.

Questions to Ask Your Doctor

  1. 1.How sure are we that this is aCML and not CML or another related condition, and should my marrow results be reviewed at a specialist center?
  2. 2.Am I a candidate for a stem cell transplant, and if so, when should we start looking for a donor?
  3. 3.What are the goals of the treatment you are recommending, and how will we know whether it is working?
  4. 4.Did gene testing find any changes that could make me eligible for a particular drug or clinical trial?
  5. 5.What signs would suggest the disease is progressing toward acute leukemia, and how often will we check?

Last reviewed • Oct 2026

Educational content, not medical advice.